Menu
8 am – 6:50 pm
BBCS 2024 – BREAST CANCER PRECEPTORSHIP / MASTERCLASS
GUESTS ONLY
Coordinator
Clinical Oncologist at Rede D´Or with a focus on female tumors. Master in Genomic Sciences and Biotechnology from UCB.
8 am – Opening
MINI CONFERENCE 1
Moderator
Pathologist from the Faculty of Medicine of USP (HC-FMUSP). Specialist in Pathological Anatomy by the Brazilian Society of Pathology (SBP) and member of the Brazilian Society of Mastology (SBM). Specialist in Breast Pathology.
8:15 am – 8:35 am
Rare subtypes of breast cancer
Doctor graduated in Medicine from the School of Health Sciences (2009); Medical Residency in the Specialty in Pathological Anatomy at the Hospital das Clínicas of the Federal University of Goiás (2010 – 2013); Title of Specialist in Pathological Anatomy by the Brazilian Society of Pathology (2014); Master's Degree in Health Sciences – PPGCS/UFG (2014 – 2017); Preceptor of the Medical Residency Program in Pathology at Hospital de Base/IGESDF (2018 - current); Lato Sensu Postgraduate Degree in Hereditary Predisposition to Cancer from Albert Einstein Instituto Israelita de Ensino e Pesquisa. Auditor of the Accreditation and Quality Control Program – PACQ – of the Brazilian Society of Pathology (2020-2021); PhD in Health Sciences – PPGCS/UNB (2018 – Current).
8:35 am – 8:45 am
Discussion
PANEL 1
Moderators:
Oncological Surgeon, Mastologist and Nutrologist. Doctor and Master in Health Sciences from UnB. Adjunct Professor of Medical Semiology at the Faculty of Medicine of PUC-GO. Member of the clinical staff at Hospital Israelita Albert Einstein - Goiânia Unit, the Institute of Mastology and Oncology (IMO) and CEBROM-ONCOCLÍNICAS.
Clinical Oncologist, Head of Oncology Research and National Breast Cancer Leader - DASA Oncologia. Postdoctoral fellow in the Department of Medical Oncology at the Dana-Farber Cancer Institute, Harvard Medical School.
Clinical Oncologist at CEBROM – Grupo Oncoclínicas. Professor at the UFG Faculty of Medicine.
8:45 am – 9:05 am
Initial HR-positive disease – clinical case discussion
Clinical Oncologist at Rede D´Or with a focus on female tumors. Master in Genomic Sciences and Biotechnology from UCB.
9:05 am – 9:25 am
The revolution in the surgical treatment of breast cancer
Mastologist at the General Hospital of Fortaleza. Member of SBM / ASCO / ASBrS. President of the commission specialized in Mastology. Co-founder of the Breast Cancer Brazil initiative.
9:25 am – 9:45 am
When to use genomic signatures in the care of our patients, and how
Clinical Oncologist, Head of Oncology Research and National Breast Cancer Leader - DASA Oncologia. Postdoctoral fellow in the Department of Medical Oncology at the Dana-Farber Cancer Institute, Harvard Medical School.
9:45 am – 10:05 am
Adjuvant hormone therapy and cyclin inhibitors. What strategies do we currently have, and how can we personalize treatment?
Clinical Oncologist - Leader of Breast Oncology at Hospital Nora Teixeira da Santa Casa de Porto Alegre. PhD in Medical Sciences from UFRGS.
10:05 am – 10:35 am
Discussion
10:35 am – 11 am
Coffee Break
PANEL 2
Moderators
Clinical Oncologist at Rede D´Or with a focus on female tumors. Master in Genomic Sciences and Biotechnology from UCB.
Medical residency in Clinical Cancerology at the National Cancer Institute (INCA), 2009-2011. Full member of the Brazilian Society of Clinical Oncology (SBOC). Full member of the Brazilian Society of Mastology (SBM). Full member of the American Society of Clinical Oncology (ASCO). Full member of the European Society of Oncology (ESMO). Observership at the Breast Unit of the Champalimaud Foundation-Lisbon, Portugal (03/2019). Observership at the Breast Unit at the Jules Bordet Institute - Brussels/Belgium, September 2022. Scientific coordinator of the Breast Cancer Service at INGOH.
Mastologist at AC Camargo Cancer Center. Master in Oncology from the Antônio Prudente Foundation (AC Camargo Cancer Center). Social Projects Committee Brazilian Society of Mastology SP. Breast Neoplasms Committee of the Brazilian Society of Oncological Surgery.
11 am – 11:20 am
HR-positive metastatic disease – clinical case discussion
11:20 am – 11:40 am
Treatment sequencing for HR-positive metastatic breast cancer
Medical Oncologist- Hospital Sírio Libanês - DF. Specialist in breast and gynecological cancer.
11:40 am – 12 pm
New therapeutic strategies in the treatment of HR-positive disease
Clinical oncologist and regional medical leader of the Oncoclínicas Group in Bahia. Former fellow of the breast oncology service at Memorial Sloan Kettering Cancer Center, NY, USA.
12 pm – 12:30 pm
Discussion
12:30 pm – 2 pm
Lunch
PANEL 3
Moderators:
Clinical Oncologist of the Oncoclinicas DF group, focused on the treatment of female tumors, oncogenetics and precision oncology. Specialist title in palliative medicine. Master's student in Oncology at Hospital Sírio Libanês.
2 pm – 2:20 pm
Clinical case of triple negative disease – initial disease
2:20 pm – 2:40 pm
Update on the systemic treatment of localized/locally advanced triple negative disease
Clinical oncologist at Grupo Oncoclínicas - DF, with an exclusive area of expertise in breast cancer.
2:40 pm – 3 pm
When to consider prophylactic mastectomy in patients with BRCA1, BRCA2 and p53 mutations, with no personal history of breast cancer?
Head, Oncogenetics Unit, Hospital Sirio-Libanes. Geneticist and PhD in Oncology from FMUSP.
3 pm – 3:20 pm
Update on systemic treatment of metastatic triple negative breast cancer and management of immune-mediated events
3:20 pm – 3:50 pm
Discussion
3:50 pm – 4:30 pm
Coffee Break
MINI CONFERENCE 2
Moderator
General Director of DF Star Hospital Executive Director - Oncologia D´Or Radiotherapy.
4:30 pm – 4:50 pm
Update on radiotherapy treatment for breast cancer. What is the trend for patients with early axillary disease who respond to neoadjuvant therapy?
Radio-Oncologist at the Cancer Hospital Araújo Jorge, the Institute of Mastology and Oncology - IMO and CEBROM Grupo Oncoclinicas of Goiânia. Master's and PhD from the Federal University of Goiás. Member of the current Board of Directors of the Brazilian Society of Radiotherapy.
4:50 pm – 5 pm
Discussion
PANEL 4
Moderators:
Clinical Oncologist at Rede D´Or with a focus on female tumors. Master in Genomic Sciences and Biotechnology from UCB.
Head doctor in the Department of Radiotherapy at Hospital Sírio-Libanês in São Paulo. Free Professor at the FMUSP Faculty of Medicine. President of the Brazilian Society of Radiotherapy.
5 pm – 5:20 pm
Clinical Case of metastatic HER2 disease, progressing in first line with CNS metastasis
Clinical Oncologist at Oncologia D`Or - DF. Medical residency at AC Camargo Cancer Center.
5:20 pm – 5:40 pm
Update on systemic treatment of metastatic HER2 disease
Medical residency in Clinical Cancerology at the National Cancer Institute (INCA), 2009-2011. Full member of the Brazilian Society of Clinical Oncology (SBOC). Full member of the Brazilian Society of Mastology (SBM). Full member of the American Society of Clinical Oncology (ASCO). Full member of the European Society of Oncology (ESMO). Observership at the Breast Unit of the Champalimaud Foundation-Lisbon, Portugal (03/2019). Observership at the Breast Unit at the Jules Bordet Institute - Brussels/Belgium, September 2022. Scientific coordinator of the Breast Cancer Service at INGOH.
5:40 pm – 6 pm
The impact of lifestyle changes on reducing the risk of breast cancer and recurrence
Oncologist specializing in female tumors and integrative oncology, working at Rede Dor in Salvador.
6 pm – 6:20 pm
To what extent and how should molecular expression influence the surgical decision in the metastatic disease?
Dr. Tadahiko Shien MD, Ph.D. (Ph.D.-surgical medicine) is a director of the Breast and Endocrine Surgery Department at Okayama University Hospital and the JCOG Breast Cancer Study Group chair. He is a surgical oncologist researching the treatment strategy for de-novo stage IV breast cancer (PI of JCOG1017 study) and Oligometastasis. His clinical and research interests primarily focus on breast surgical oncology, tumor biology, clinical trials, and translational research. He is a member of the American Society of Clinical Oncology (ASCO), Japan Surgical Society (JSS), Japan Society of Clinical Oncology (JSCO), Japan Breast Cancer Society (JBCS), Japan Society of Medical Oncology (JSMO), International Society of Surgery (ISS), Japan Oncoplastic Breast Surgery Society (JOBSS), Japan Association of Endocrine Surgery (JAES), and Breast Surgery International (BSI). His board-certified specialties are JSS, JSCO, and JAES, and the Board of JBCS and JAES. He is an associate editor of BMC Women’s Health, Frontier in Oncology, and Oncology letters.
6:20 pm – 6:50 pm
Discussion
6:50 pm
Closing
